technology

press releases

Date Title and Summary Additional Formats
Toggle Summary BOTHELL, Wash., March 06, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data for eptinezumab (formerly ALD403), which is in clinical development for the prevention View HTML
Toggle Summary 2016 Clinical Data Support Eptinezumab's Potential to Deliver a Unique Combination of Speed to Clinical Benefit and Effectiveness That Persists for at Least Three Months After a Single Administration Top-Line Data from First Pivotal Phase 3 Study, PROMISE 1, On Track for First Half 2017 Conference View HTML
Toggle Summary BOTHELL, Wash., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its fourth quarter and full year 2016 financial and operating results View HTML
Toggle Summary BOTHELL, Wash., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming Leerink Partners 6th Annual Global Healthcare View HTML
Toggle Summary BOTHELL, Wash., Jan. 02, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming 35th Annual J.P. View HTML
Toggle Summary Eptinezumab Selected as the International Nonproprietary Name for ALD403 View HTML
Toggle Summary BOTHELL, Wash., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast a business overview and update by members of the management team at each of View HTML
Toggle Summary Company Finalizes ALD403 Pivotal Program Design and Confirms Planned Initiation of PROMISE 2 Phase 3 Study in 2016 Top-Line ALD403 PROMISE 1 Phase 3 Data Expected in First Half of 2017  BOTHELL, Wash., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. View HTML
Toggle Summary BOTHELL, Wash., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its third quarter 2016 financial and operating results after the close of View HTML
Toggle Summary BOTHELL, Wash., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage company developing monoclonal antibody therapeutics, today announced the promotion of Larry Benedict to the position of Executive Vice President and Principal Accounting Officer. Mr. View HTML